As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
Bliss is Hetero Healthcare’s dynamic multi-speciality division that brings diverse therapeutic expertise under a multi-speciality platform. This division focuses on comprehensive solutions across anti-allergics, anti-infectives, gastrointestinal, dermatology, and cough care. It combines quality formulations with a patient-centric approach to meet diverse healthcare needs.
Bliss Division's growing portfolio reflects Hetero Healthcare's focus on innovation, affordability, and accessible treatment across multiple specialities. Explore Bliss Division products designed to support better health outcomes for patients and healthcare professionals.
View by-